

TOP 10 REASONS TO IMPLEMENT ENDOTOOL IV

With EndoTool IV eGMS, patients achieve glycemic control safely and quickly, meaning they are less likely to acquire subsequent infections, they avoid spending additional time in expensive critical care units and their overall hospital length of stay is reduced by one day on average. Here are a few reasons EndoTool by Monarch has been trusted for over 16 years.

TRUSTED SOFTWARE FOR GLYCEMIC MANAGEMENT

EndoTool IV has been implemented in more than 300 hospital facilities and offers safer inpatient glucose management care.

EREI CALCULATION

Only available from EndoTool IV, the Estimated Residual Extracellular Insulin (EREI), or the residual insulin present in a patient's body, is factored into insulin dosing recommendations.

SEAMLESS EMR INTEGRATION

Capable of full integration with all major Electronic Medical Record (EMR) systems, EndoTool is easily deployed with any hospital IT network and is backed by around-the-clock support from Monarch's team of clinical and IT experts.

REDUCED LENGTH OF STAY

On average, patients in intensive care who are using EndoTool IV see a reduction in their length of stay by one day, saving expenses for both patients and hospitals.

PERSONALIZED TREATMENT

Insulin dosing recommendations are based on 11 patient-specific factors including creatine levels, kidney function, and steroids with EndoTool so patients receive the most precise dose.

CONTINUED





TOP 10 REASONS TO IMPLEMENT ENDOTOOL IV

With EndoTool IV eGMS, patients achieve glycemic control safely and quickly, meaning they are less likely to acquire subsequent infections, they avoid spending additional time in expensive critical care units and their overall hospital length of stay is reduced by one day on average. Here are a few reasons EndoTool by Monarch has been trusted for over 16 years.

SIMPLE, CUSTOMIZABLE PROCESS

With EndoTool, the software can also be customized with recommended parameters for each unit to streamline care and add a layer of consistency across a hospital's system.

DECREASED RISK OF HACS

Studies have shown with EndoTool IV, hospital-acquired conditions (HAC) are reduced by 61%, assisting in keeping patients safe during their hospital stay.

MEETS THE NEEDS OF ALL PATIENT TYPES

EndoTool's predictive and adaptive technology helps stabilize even the most challenging patient cases within three hours on average. EndoTool IV includes a custom mode of therapy, EndoX, with insulin dosing recommendations for extreme health events like diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemia nonketotic syndrome (HHS).

NEAR ZERO HYPOGLYCEMIC EVENTS

With EndoTool IV, hypoglycemia with blood glucose readings less than 70mg/dL is reduced to 0.36%, while hypoglycemia with blood glucose readings less than 40mg/dL is statically eliminated with a rate of 0.009%.

A SAFER SOLUTION

EndoTool predicts and modifies a patient's dose trajectory to mirror their unique physiological response until a target range is reached, meaning patients receive safer, individualized care.

